Cytokinetics (CYTK) (NASDAQ:CYTK)公佈季度虧損爲每股$(1.26)，低於分析師的一致預期$(1.17)，相差7.69%。這一結果較去年同期每股虧損$(1.38)增長了8.7%。公司報告季度銷售額爲1692.7萬美元，遠高於分析師一致預期的174.2萬美元，超過了871.94%。這一結果較去年同期167.2萬美元的銷售額增長了912.38%。

以上內容來自Benzinga Earnings專欄，原文如下：

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.17) by 7.69 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $16.927 million which beat the analyst consensus estimate of $1.742 million by 871.94 percent. This is a 912.38 percent increase over sales of $1.672 million the same period last year.